$11.2 Million Net Loss for PharmaPrint

Drug developer PharmaPrint Inc. reported a net loss of $11.2 million, or $1.10 a share, for the year ended March 31, which included one-time stock compensation charges of $5.3 million. That compares with a net loss of $1.3 million, or 16 cents a share, for the previous year. A net loss of $2.2 million, or 19 cents a share, was posted for the fourth quarter, compared with a net loss of $505,171, or 6 cents a share, for the like period last year. No revenue was reported.